Hostname: page-component-586b7cd67f-2brh9 Total loading time: 0 Render date: 2024-11-24T18:27:34.494Z Has data issue: false hasContentIssue false

Starting Digital Treatment for Neurodevelopmental Disorders by Experience Experts: On the Waiting List for Diagnostic Assessment via the Super Brains App

Published online by Cambridge University Press:  01 September 2022

J.J.S. Kooij*
Affiliation:
Super Brains BV, Oud Beijerland, Netherlands
R. Den Hollander
Affiliation:
Super Brains BV, Oud Beijerland, Netherlands
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Digital treatment for neurodevelopmental disorders is being developed in order to treat patients online when possible, to reduce waitinglists, and to improve efficiency of treatment. In this workshop, first experiences with the so called Start Programme of the Super Brains app for ADHD in adults are presented. The Super Brains app has been developed by Rutger den Hollander, who himself has ADHD and owns an ICT company in the Netherlands, in cooperation with the speaker of this workshop and Parnassiagroep. The Start Programme is a new part of the Super Brains app, meant for patients referred for treatment that have to wait on often long waitinglists. Now they have no longer to wait, but can start immediately preparing for assessment by filling in questionnaires, and with psycho-education, lifestyle tips and support by experience experts that welcome them in the app and show them around. First data on the use of different parts of the Start Programme, the activity of patients in the app, and the satisfaction of patients will be presented. We also aim to study whether the Start Progamme is effective in reducing severity of ADHD symptoms. Super Brains can be adjusted for use in patients with other (neurodevelopmental) disorders easily.

Disclosure

No significant relationships.

Type
Educational
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.